News

Ferring’s Microbiome Health Index is a diagnostic tool that may help distinguish a healthy gut microbiome from post-antibiotic dysbiosis, and could potentially identify debilitating illnesses such as C difficile infection

New data suggests an additional “booster” dose of an mRNA COVID-19 vaccine is no longer just recommended but required for protection against the infectious Omicron variant.

The single-center study suggested shoes are a common transmission route, but also hinted at a diverse web of transmission involving humans, animals, and the environment.

Vaccine hesitancy is a significant hurdle experienced in the US. In response to this, a team of researchers analyzed adults who reported a medical provider recommended the COVID-19 vaccine, studied vaccination status, and general attitudes.

Dolutegravir-based antiretroviral therapy proved more effective than standard treatments for HIV-positive children, reducing treatment failure by 40%.

After increased awareness soon after the emergence of COVID-19, fewer Americans see plight of people of color.

The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.

The CDC recommends all pregnant women receive a COVID-19 vaccine, finding vaccination does not increase risk of preterm birth or small-for-gestational-age at birth.

In the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.

A pregnant woman is reported to be the country’s first person to be infected simultaneously with COVID-19 and influenza.

A new study found states that offered monetary prizes to randomly selected vaccinated persons did not have significant increases in vaccine uptake.

Underweight elderly pneumonia patients were more likely to contract C difficile infection.

Novavax’s COVID-19 vaccine demonstrated 90.4% efficacy in a phase 3 trial with no moderate or severe cases reported among participants in the treatment group.

The country says one city hospital’s data shows a decrease in severity and mortality during this latest variant's outbreak.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

Immigrant communities may be more hesitant to disclose personal health information due to fears of bullying or deportation, a new study finds.

Investigators compared pre- and post-intervention data points at 4 clinics in Kenya.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

COVID-19 patients who underwent prior weight-loss surgery were significantly less likely to experience severe disease outcomes.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

The oral antiviral therapy proceeds the first indication for the drug class by just a day; the US will now have multiple pills to treat COVID-19.

In a study of more than 600 elderly Japanese, being overweight was a protective factor against Clostridioides difficile infection (CDI).

Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP are aiming to increase users.

This is the first pill to treat COVID-19 in trying to prevent progression to severe disease and possible hospitalization.

COVID-19 patients were not at increased risk of Clostridium difficile infection. However, those already infected with C diff were more likely to experience severe outcomes.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.